Delving into the Latest Updates on OOO NPF Materia Medica Holding with Synapse

Overview

Tags

Nervous System Diseases

Cardiovascular Diseases

Other Diseases

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Monoclonal antibody	1

Background:Our research investigates how the structure of a lactose matrix can be altered by the specific drugs used to saturate it. In particular, we examine whether ultra-high dilutions of substances, such as antibodies, can change the crystal structure of lactose.Methods:We employed methods including X-ray diffractometry, Raman spectroscopy, and granulometric content analysis.Results:Our findings suggest that once saturated with highly diluted substances, lactose does indeed gain and retain changes in its crystalline structures [particularly cell parameters a, b, c, β]. These changes are most pronounced between intact and saturated lactose samples, and there are also differences observed when using different solutions for saturation.Conclusion:The results support the idea that ultra-high dilutions can irreversibly change the structure of lactose, potentially due to differences in solution wetting and subsequent recrystallization of the lactose matrix.

01 Jul 2024·Dose-Response

Biological Medicines Prepared Using Vibration Processing Are Able to Influence Their Targets Without Direct Contact With Them

Article

Author: Don, Elena ; Petrova, Anastasia ; Yaroshenko, Sabina ; Tarasov, Sergey ; Zakharova, Svetlana

Recently, there has been a radical change in understanding of the nature of drugs based on highly diluted solutions. It has been established that their activity does not depend on the content of the original substance in dilutions, but is a consequence of the technological processing (TP) of dilutions with vibration, which accompanies each dilution during the preparation of solutions and, among others, leads to the formation of nanoparticles with certain properties. Repeated vibration treatment leads to the appearance of modifying activity that is absent in the original substance, and these effects of TP solutions can be exerted without direct contact with their targets, which clearly indicates the physical nature of the TP solution’s activity. In the framework of this article, a statistically significant effect of TP antibodies to the insulin receptor on glucose consumption by CHO cells both with and without contact exposure, as compared with control ( P < 0.05) was shown in the vast majority of the experiments. The obtained results shed light on a possible source of activity of drugs based on TP antibodies, which should be associated with the applied vibration effect and can manifest itself both with contact exposure and without it.

01 Feb 2024·Physics of Wave Phenomena

The Effect of Aqueous Solutions Processed Using Gradual Technology on the Emission of a Carbohydrate (Lactose) in the RF Range

Author: Chernikov, D. Yu. ; Novikov, V. V. ; Tarasov, S. A. ; Yablokova, E. V. ; Rodionova, N. N. ; Fedorova, M. M. ; Minakov, A. V. ; Boriskin, V. S. ; Petrova, A. O. ; Stepanov, G. O.

Treatment of antibodies using gradual technol. implies a series of successive dilutions, accompanied by mech. impacts, with subsequent saturation of lactose with the obtained solutionIn comparison with intact lactose, the resulting products have increased emission in the RF frequency range from 50 MHz to 3.5 GHz.

100 Deals associated with OOO NPF Materia Medica Holding

Login to view more data

100 Translational Medicine associated with OOO NPF Materia Medica Holding

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Approved

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

S-100 protein antibody(Materia Medica Holding)	Anxiety Disorders More	Approved
MMH-MAP	Ischemic stroke More	Phase 3
MMH-407	Influenza, Human More	Suspended
Subetta	Glucose Intolerance More	Pending
Afalaza ( KLK3 )	Prostatic Hyperplasia More	Pending